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Abstract
TARGETED MOLECULAR THERAPIES IN GASTROINTESTINAL CANCERS AND
CANCER CACHEXIA
Scott E. Mulder, Ph.D.
University of Nebraska Medical Center, 2020
Supervisor: Pankaj K. Singh, Ph.D.
Hepatocellular carcinomas exhibit metabolic alterations to support their
proliferative and biosynthetic needs. We identified that elevated expression of the
mitochondrial oxidative carboxylase, malic enzyme 2 (ME2), correlates with poorer
hepatocellular carcinoma patient survival. Hepatocellular carcinoma patient tumors with
high ME2 expression exhibit transcriptomic alterations indicative of PI3K/AKT/mTOR and
c-Myc signaling as well as elevated central carbon, fatty acid, and redox metabolism
pathways. Depletion of ME2 in the hepatocellular carcinoma cell line PLC or in the livers
of mice treated with diethylnitrosamine to chemically induce hepatocellular carcinomas,
results in impaired proliferation and reduced tumor formation. Additionally, the loss of ME2
results in reduced protein levels of c-Myc in both models and diminished activation of the
PI3K/AKT/mTOR signaling pathway in PLC cells. Increased c-Myc levels in ME2
expressing cells may be due to the overexpression of CIP2A, which stabilizes c-Myc by
preventing its proteolytic degradation. Inhibition of mTOR with Everolimus was equally
effective at impairing PLC cell viability, regardless of ME2 expression status. Liquid
chromatography-tandem mass spectrometric analysis revealed that the loss of ME2 not
only reduces glycolysis and TCA Cycle intermediates but also diminishes metabolites
involved in the glutathione antioxidant pathway and fatty acid metabolism. Overall, these
data suggest that ME2 supports hepatocellular carcinoma cell proliferation, and that
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targeting the enriched c-Myc and PI3K/AKT/mTOR pathways may be an effective
therapeutic, particularly in combination therapy, even though no selectivity was observed
in the cell line we tested.
Cancer patients commonly experience a complex metabolic syndrome called
cachexia, which notably results in body weight loss and muscle wasting. Significant
muscle wasting not only impairs the quality of life but also impacts the treatment efficacy
for patients. Skeletal muscle protein turnover is imparted by increased expression of
ubiquitin-proteasome pathway components. Mitogen-activated protein kinases p38 and
ERK have been shown to augment E3 ubiquitin ligase expression. Utilizing reverse-phase
protein arrays, we identified pancreatic cancer cell-conditioned media-induced activation
of JNK signaling in myotubes differentiated from C2C12 myoblasts. Inhibition of JNK
signaling with SP600125 reduced cancer cell-conditioned media-induced myotube
atrophy, myosin heavy chain protein turnover, and mRNA expression of cachexia-specific
ubiquitin ligases Trim63 and Fbxo32. Furthermore, utilizing an orthotopic pancreatic
cancer cachexia mouse model, we demonstrated that treatment of tumor-bearing mice
with SP600125 improved longitudinal measurements of forelimb grip strength. Postnecropsy measurements demonstrated that SP600125 treatment rescued body weight,
carcass weight, and gastrocnemius muscle weight loss without impacting tumor growth.
JNK inhibitor treatment also rescued myofiber degeneration and reduced the muscle
expression of Trim63 and Fbxo32. These data demonstrate that JNK signaling contributes
to muscle wasting in cancer cachexia, and its inhibition has the potential to be utilized as
an anti-cachectic therapy.
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Chapter 1: Introduction
Cancer is an immense global burden as the disease is the second-leading cause
of death in the United States and worldwide [1]. Gastrointestinal (GI) malignancies are
cancers deriving from the gastrointestinal tract and other organs that affect digestion. GI
cancers are responsible for over a quarter of the new cancer cases and almost 40% of
cancer deaths worldwide [1]. Herein, GI malignancies of the pancreas and liver will be
examined as well as cancer cachexia.

Hepatocellular Carcinoma
Epidemiology
Liver cancer is a morbid GI malignancy that is pervasive in our society. The disease
is the 13th most common cancer in the United States and the seventh most in the world
[1, 2]. Cirrhosis from any cause increases the likelihood of hepatocellular carcinoma
(HCC); particularly if it is due to Hepatitis C Virus (HCV), Hepatitis B Virus (HBV), nonalcoholic fatty liver disease [3]. Its incidence in the United States has risen two- to threefold in the last 30 years due to higher rates of HCV and metabolic liver diseases such as
fatty liver disease [4]. The increase in incidence of liver cancer is actually the highest of
any malignancy in the United States over roughly the last decade and a half [5]. Liver
cancer is accountable for the sixth most cancer deaths in the United States and the second
most worldwide [1, 5]. HCC the primary liver malignancy as it is responsible for 80-90% of
liver cancers worldwide [6]. The survival rate for HCC widely varies based on location:
North America (33%), Europe (24%), and Africa-excluding Egypt (2-3%) [7]. Liver cancer
patients in the United States only have a 5-year survival of 22% and 18% for patients with
regional or distant disease, respectively [5]
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Development and Genetic Landscape
Livers are a multi-lobular organ that contribute to digestion, immunity,
detoxification, and metabolism among other functions [8-10]. Each lobe is often associated
with a hexagonal organization with three layers, called zones 1 to 3, surrounding a central
vein; each zone experiences gradients of oxygen and resources as well as exhibit
characteristic functions [10, 11]. Hepatocytes are the most abundant and constitute 80%
of the mass of the organ are responsible for producing bile, which is important for digestion
and absorption of lipids [12].
Most cancers have developmental patterns that occur in a relatively stochastic or
canonical manner and HCC is no different. Infection (HBV and HCV) and environmental
factors (alcohol and aflatoxin) are among common insults or contributors to advance
normal tissue to pre-neoplastic stages [13, 14]. Hepatitis is integral in the progression of
HCC and it develops from chronic inflammation and oxidative stress, which results in cell
death, regeneration, and ultimately fibrosis [13, 15]. It is also commonplace in the
progression of HCC for elevated levels of triglycerides a spectrum that can be classified
as non-alcoholic fatty liver disease (NAFLD). The level of inflammation, triglyceride
retention, and other insults or genetic modifiers cause the liver tissue to progress from
simple steatosis, to non-alcoholic fatty liver (NAFL), and to non-alcoholic steatohepatitis
(NASH) which most likely can result in cirrhosis and possibly HCC [16]. As much as 8090% of HCC patients have underlying cirrhosis [17, 18]. While infrequent, it is possible for
HCC to develop from hepatocellular adenomas [19]. Cirrhotic livers and neoplasias require
genetic and epigenetic alterations to generate HCC.
Malignant transformation for neoplastic hepatocytes is accompanied by genetic
and epigenetic aberrations. The most common mutation in HCC is that of the promoter for
telomerase (TERT) and it occurs in up to 65% of cases [13, 20-22]. It is a driving force in
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transformation and can be found in premalignant lesions, becomes more frequent in early
stages of HCC, and ultimately over-activation of telomerase is observed in 90% of HCC
cases [20, 23-25]. Other highly mutated genes include TP53 (30-60%) and CTNNB1 (2740%) [13, 23, 26-28]. TP53 mutations correlate with reduced patient survival [22, 26].
Many other mutations occur at lower frequencies including ARID1A (10-16%), NFE2L2
(NRF2; 6-10%), JAK1 (9%), AXIN1 (4-9%), and KEAP1 (3-8%) [25, 29, 30]. Multiple EGFR
family members (21-68%) and c-Myc (40-70%) are found to be overexpressed in many
HCC patient tumors [24, 25, 31].

Treatment Options
Consistent with most solid tumors, surgical resection is a preferred course of
action, but this can only take place when found at a very early stage and only occurs in
20% of cases [3, 32]. The 5-year survival rate for surgery is just above 50% [33]. However,
around 70% of patients that undergo resection ultimately experience recurrent disease
[34]. Liver transplantation is another surgical treatment option with high effectiveness
when resection is not possible, and it has a tremendous 5-year survival rate for HCC
patients at greater than 70% [35]. The benefit of transplantation is that it not only removes
the tumor but also addresses the underlying liver disease which could lead to new
malignancies [36]. For patients with intermediate HCC, variants of ablation or transarterial
chemoembolization (TACE) are often implemented [3]. Advanced disease is addressed
by systemic chemotherapy, and first-line therapies for advanced HCC are multi-kinase
inhibitors Sorafenib and Levnatinib [7, 37]. Sorafenib targets vascular endothelial growth
factor receptors (VEGFR)1-3, platelet-derived growth factor receptor (PDGFR)- β, and the
Raf kinases [7]. While Lenvatinib targets VEGRF1-3, PDGRF-α, fibroblast growth factor
receptors (FGFR)1-4, RET, and KIT [7]. Other targeted monotherapies exist but have not
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led to therapeutic improvements on their own in most cases, but ongoing studies are
further exploring their potential [25, 38].
As with most cancer, there is growing investigation into immunotherapies in HCC.
Anti-PD-1/PD-L1, anti-CTLA4, and other immune checkpoint inhibitor monotherapies
have been tested but have largely resulted in unimpressive results [38]. However,
combination immune checkpoint inhibitor-based therapies have displayed greater
potential, including nivolumab (anti-PD-1) and ipilmumab (anti-CTLA-4) combination has
improved upon monotherapy, and evaluation of efficacy in comparison to first-line
standard-of-care therapies is ongoing

[38, 39]. Atezolizumab (anti-PD-L1) and

veacizumab (anti-VEGF) have been found to improve survival, compared to Sorafenib, in
unresectable HCC patients naïve to systemic therapy [40]. Cytokine-induced killer cellbased adoptive cell transfer has shown potential to extend survival for previously
untreated HCC patients and when given as adjuvant therapy [41, 42]

Pancreatic Ductal Adenocarcinoma
Epidemiology
Pancreatic cancer is a devastating GI malignancy that is among the most lethal
cancers. The malignancy is the 11th most common in the United States and 14th globally
[1, 5]. However, the overwhelming lethality of the disease makes it responsible for the third
most cancer deaths in the United States and seventh worldwide [1, 5]. These grim
statistics are expected to worsen due to recent rising trends in the incidence of pancreatic
cancer, and the malignancy is projected to be the second-leading cause of cancer by 2024
[5, 43]. The 5-year survival for all pancreatic cancer stages is a dismal 8-9% despite recent
improvements in therapy [44]. Contributing to the lethality of the disease is the stage at
diagnosis; more than half of pancreatic cancer patients are diagnosed with advanced
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disease that has spread to distant sites [44]. Patients with distant disease have an
abhorrent 3% 5-year survival rate [44]. Pancreatic ductal adenocarcinoma (PDAC) is the
most predominant type of pancreatic neoplasm and constitutes approximately 85-90% of
the tumors [45, 46].

Development and Genetic Landscape
The pancreas is an organ located distal to the stomach in the abdomen and is
surrounded by other GI organs, and it aids in digestion and modulates blood glucose levels
[47, 48]. The function and morphology of the pancreas can be bifurcated into the exocrine
and endocrine pancreas. The majority (95%) of the organ is the exocrine compartment
comprised of the acinar and ductal cells [49]. These cells produce digestive enzymes into
the pancreatic ducts which ultimately reach the small intestine [48]. The exocrine
compartment is responsible for blood glucose regulation, and its cells organize into
groupings called islets of Langerhans [50, 51]. The islet cells release hormones into
vasculature: a-cells (glucagon), b-cells (insulin), d-cells (somatostatin), e-cells (ghrelin),
and γ-cells (pancreatic polypeptide) [50]. Pancreatic cancer can form from either
pancreatic compartment, but they occur at varying frequencies and have vastly different
outcomes. Five percent or less of pancreatic cancers derive from endocrine tissue [52].
These patients have a much better probable outcome as they have approximately a 54%
5-year survival rate, and that is statistic is above 90% for patients with only local disease
[53]. Exocrine-derived tumors are the most common and roughly 85-90% of pancreatic
cancers are of this type, and the five-year survival for all PDAC patients is 8-9% [5, 45,
46].
PDAC is associated with numerous precursor lesions: intraductal oncolytic
papillary neoplasms, intraductal papillary mucinous neoplasms, intraductal tubulopapillary
neoplasms, mucinous cystic neoplasms, and pancreatic intraepithelial neoplasias
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(PanINs) [54]. PanINs are the common precursor lesion derived from cuboidal or columnar
epithelial cells and are characterized as microscopic, non-invasive epithelial neoplasia
with varying morphological over their evolution from low-grade PanINs (formerly PanIN-1
or -2) to high-grade PanINs [55-57]. Low-grade PanINs are either flat or projecting
(papillary) lesions, exhibit some atypia, express the mucins MUC5AC and MUC6, and
have nuclei with mostly basal polarity [54, 56, 57]. High-grade PanINs are papillary lesions
with high levels of atypia, express the mucin MUC1, and exhibit a complete loss of polarity
[54, 56, 57]. As PanINs progress to PDAC, there are increasing levels of desmoplasia,
hypoxia, and characteristic frequencies of mutations [58].
The mutational landscape in the development of PDAC is primarily thought to be
stochastic due to the observed incidences of genetic alterations. Pancreatic exocrine cells
are fluid in their phenotypes as acinar cells commonly transdifferentiate to be more ductallike (acinar-to-ductal metaplasia) under various conditions; during this evolution the cells
are vulnerable to mutations that lead to precursor lesions [59]. KRAS is mutated in 9095% of pancreatic cancers, more than 99% of low-grade PanINs have mutations or copy
number alterations, and it is thought these activating aberrations are the initiating step
towards PDAC [60, 61] Cyclin-dependent Kinase Inhibitor 2A (CDKN2A; also known as
p16) is inactivated in more than 90% of PDAC via multiple mechanisms [62, 63]. It occurs
in late low-grade PanINs (PanIN-2) and increases with progression. Inactivating mutations
in TP53 and SMAD4 occur at rates of up to 85% and 55-60%, respectively; these
mutations primarily begin to occur in high-grade PanINs [64-68]. Other mutations occur in
a much smaller population of PDAC patients and might be keys to precision medicine [43,
69, 70].
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Treatment Options
Discoveries in the treatment of pancreatic cancer have made marginal over the
last decades. Survival rates in the early 1970s were only 2.5%, 10-years ago it was 5%,
and now it is only improved to 8-9% [44, 71]. Surgical resection remains the option with
the potential for curative treatment or long-term survival [71]. Patients that receive surgical
resection without adjuvant treatment have a 5-year survival rate of approximately 10%;
surgery with adjuvant chemotherapy has been shown to be superior to surgical resection
alone with a survival rate of up to 25% [72-75]. Only 15-20% of patients present with tumor
staging that eligible for surgical resection [76-79]. Therefore, while surgical resection is
the treatment to which should be aspired, the reality is that most patients require systemic
chemotherapy or other advanced strategies.
Systemic chemotherapy is the mainstay treatment for pancreatic cancer patients
with advanced disease or borderline-resectable tumors. Gemcitabine (GEM), a
deoxycytidine analog, became the standard-of-care chemotherapeutic in the [71]. Variants
of the multi-drug treatment called FOLFIRNOX (fluorouracil, leucovorin, irinotecan, and
oxaliplatin) or the combination of GEM + nanoparticle albumin-bound (nab)-paclitaxel
have since shown their superiority and become the new standard first-line chemotherapies
[61, 80, 81]. No clinical trial has directly compared the efficacy of FOLFIRINOX with GEM
+ nab-paclitaxel. However, these therapies are taxing and are only given to patients with
good health or performance status; patients with poor performance status receive GEMbased therapies [79]. Targeted therapies may provide the necessary strategy to improve
pancreatic cancer therapy further.
The absence of targeted therapy in PDAC has been slow to gain traction primarily
due to the poor targetability of the main driver mutations (KRAS, TP53, CDKN2A,
SMAD4). Recently some efficacy has been shown in treating patients with targeting
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KRASG12C with a covalent inhibitor that acts during the nucleotide cycling of the protein,
but this mutation only occurs in less than 2% of PDAC patients [82-85]. Targeted therapies
focusing on downstream targets of the driver mutations or infrequent actionable targets
may be the necessary course of action to improve pancreatic cancer outcomes. Precision
medicine which treats each tumor based on its molecular characteristics will hopefully
realize advances in pancreatic cancer care.
Immune therapy in pancreatic cancer is a possible frontier for the treatment of
pancreatic cancer. Strategies attempted include checkpoint inhibitors, vaccines, adoptive
cell transfer, and combinations with or without radiotherapy or chemotherapy [86]. Low
immunogenicity, tumor-suppressive microenvironments, and extensive desmoplastic
reaction in pancreatic cancer provide some rationale for demoralizingly poor
immunotherapy results in pancreatic cancer [86]. Emerging research demonstrates that
checkpoint blockage in PDAC patients with mismatch repair deficiency or microsatellite
satellite instability is an effective strategy [87, 88]. Targeted-multifocal therapies targeting
tumors, tumor microenvironments, and the immune system may provide the pancreatic
cancer durable treatment response for which cancer research is aspiring.

Cancer Cachexia
Epidemiology
Cancer cachexia is highly prevalent for oncology patients. Approximately half of
cancer patients are believed to experience cancer cachexia [89, 90]. Advanced stage
cancer patients experience cachexia at rates around 80% [91, 92]. It is believed that an
estimated 527,000 patients are afflicted by cancer cachexia in the United States [93].
Cancer cachexia is most commonly observed in GI cancers and late-stage malignancies;
around 80% of upper GI cancers display appreciable weight loss at the time of cancer
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diagnosis [94, 95]. Pancreatic cancer patients endure cancer cachexia at the highest rate
of up to 85% [94, 96]. It is estimated that 20-40% of all cancer patients and around a third
of pancreatic cancer patients are believed to die because of cancer cachexia [94-97].

Definition and Diagnosis
Cachexia has been a long-observed phenomenon, and Hippocrates is even
credited with describing the condition over 2000 years ago [98, 99]. Cachexia is
associated with many chronic illnesses like acquired immunodeficiency syndrome,
congestive heart failure, chronic kidney disease, chronic obstructive pulmonary disease,
rheumatoid arthritis, and cancer [99, 100]. It took until 2011 to generate an international
consensus on a definition for the clinical diagnosis of cancer cachexia [101]. It is a complex
metabolic disorder, often referred as a multifactorial syndrome, and is characterized by
systemic inflammation, weight loss, and sarcopenia with or without lipoatrophy that leads
to progressive functional impairment [101-103]. The weight loss experienced in cancer
cachexia is primarily the result of muscle wasting, which makes it distinct from weight loss
caused by starvation where adipose tissue is depleted and lean tissue is mostly preserved
[104, 105]. Additionally, standard nutritional care is unable to completely reverse the
condition [101].
The prevailing symptoms for diagnosis include: weight loss greater than 5% in the
past six months, body mass index (BMI) of less than 20 and weight loss greater than 2%,
or sarcopenia and weight loss greater than 2% [101]. Cachexia can be segregated into a
spectrum (pre-cachexia, cachexia, refractory cachexia) based on the severity of their
symptoms [101]. Refractory cachexia is insensitive to nutritional interventions and
palliative care becomes the priority [101]. Cachexia not only diminishes physical ability
and quality of life, but it is also impactful in cancer care as it decreases tolerability of cancer
treatments and diminishes patient survival [89, 94, 106-109]
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Pathophysiology and Molecular Mechanisms of Muscle Wasting
Cancer cachexia is genuinely a complicated multi-organ metabolic disorder, which
contributes to the poor understanding of its mechanisms. Patients tend to develop
anorexia despite an increase in patient resting energy expenditure, but additional
nutritional support is unable to mitigate the weight and muscle loss [109]. Systemic
inflammation, tumor secreted factors, and an interplay between many organs underlie its
pathogenesis [110]. Ultimately, the disease results in a negative energy imbalance and
characteristic reduction in weight and muscle [104]. Herein, I will describe more in-depth
the pathophysiology and molecular mechanisms of muscle wasting that define cancer
cachexia.
Skeletal muscle wasting in cachexia is a balance of anabolism and regeneration
versus catabolism and apoptosis. Elevated catabolism is a hallmark of cancer cachexia;
there is increased protein degradation and increased muscle cell death during [111, 112].
Systemic inflammation, generated from both tumors and the host, is a major contributor
to muscle wasting in cancer cachexia [110]. Various cytokines induce transcription factors
connected to wasting in muscle as well as fat [113]. Hyper-activation of the ubiquitinproteasome pathway constitutes much of the elevated proteolysis in cancer cachexia
[114]. Muscle-specific E3 ubiquitin ligases Atrogin1, also known as F-box protein 32,
(Fbxo32) and muscle RING finger-containing protein 1 (MuRF1; Trim63) are major
contributors

to

ubiquitin-proteasome

pathway-mediated

degradation

[115-119].

Inflammatory mediators and secreted factors such as TNF- α, interleukins (IL)-1 and IL-6,
myostatin, activin A, and proteolysis inducing factor (PIF) promote the Atrgoin1 and
MuRF1 expression via activation of forkhead box O (FOXO) family and NF-κB
transcription factors among others [120-122]. Myostatin, PIF, and various cytokines can
initiate mitogen-activated protein kinase (MAPK)- or Janus Kinase (JAK)-induced cell
death [112]. Decreased levels of insulin-like growth factor 1 (IGF1) also augment protein
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degradation via reduced activation of phosphoinositide 3-kinase (PI3K) and protein kinase
B (AKT) signaling; development of insulin resistance also can induce the ubiquitinproteasome pathway via the same pathway as well as other mechanisms [123-127].
Elevated autophagy has also been shown to contribute to proteolysis in cancer cachexia
[112, 120, 123].
Depressed anabolism and cell death are also distinctive of muscle wasting in
cancer

cachexia.

Muscles

demonstrate

decreased

protein

synthesis,

reduced

regeneration, and increased cell death during cancer cachexia [111, 112, 128]. Decreased
IGF1 levels and the resulting reduction in PI3K/AKT/mammalian target of rapamycin
(mTOR) not only increases E3 ubiquitin ligase expression but also depresses protein
synthesis [124, 129]. Myostatin-induced signaling also has the ability to inhibit AKT via
the SMAD complex and thus repress protein synthesis [130, 131]. Diminished amino acid
pool availability is another contributor to reduced protein synthesis in cancer cachexia
[120]. Impaired muscle cell regeneration is another feature of dysfunctional muscle
maintenance in cancer cachexia [112, 132, 133]. Impaired differentiation of satellite cells
(can activate and proliferate but can’t differentiate due to constant paired box 7 (Pax7)mediated repression of essential differentiation factors) [104, 133].

Treatment and Management
Effective treatment and management of cancer cachexia have yet to be
discovered. This is again in part due to the complexity of the disease and the interplay
between tumors and numerous host organs [110]. Since the development of an
international standard for cancer cachexia in 2011, it appears that there hasn’t been
universal integration and implementation of diagnostic standards in clinical practices [134,
135]. Even if cancer cachexia is diagnosed, therapeutic strategies fail to improve upon all
facets of cancer cachexia. Strategies for cancer cachexia can generally be bifurcated into
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two strategies; either improving nutritional status or targeting dysfunctional metabolism
[136].
Cancer cachexia patients face a complicated scenario around food and nutrition.
Cachectic patients exhibit elevated resting energy expenditure, and yet anorexia and
malabsorption of what they do eat further imbalances weight maintenance in the negative
direction [109, 121, 137]. Standard nutritional interventions aiming to increase calorie
intake are not a curative, but they do improve the quality of life for patients and have been
found to prolong survival [134, 138]. Patients experiencing complications orally consuming
food may receive parenteral nutrition intravenously, which has been shown to give some
benefits to pancreatic cancer patients [134, 139-141]. Modulating diets to be ketogenic or
supplementing with omega-3 fatty acids or certain amino-acids have been attempted with
varying degrees of improvement in cachectic parameters [134, 142]. Stimulating appetite
is another major approach to addressing caloric deficiencies in cancer cachexia patients.
Megestrol acetate, a progesterone derivative, treatment is one of the most common
strategies and has been shown to increase appetite, weight, lean mass, and physical
performance [137, 143, 144]. Ghrelin or mimetics, melanocortin-4 antagonist, anamorelin,
and serotonin antagonist include some other therapeutic strategies aimed at increasing
appetite [145-149].
Disruption of metabolic disturbances is another key area of cancer cachexia
therapeutics. Blockade of pro-cachectic secretions and antagonism of anti-cachectic
secretions a principal area of focus due to the pleiotropic impact of the cytokines and
inflammatory mediators [136]. TNF-α based strategies including anti-TNF-α monoclonal
antibodies, thalidomide, and others have either failed to show improvements in cachectic
parameters or have not been able to replicate efficacy in late-stage clinical trials [150152]. However, anti-IL-6 antibody treatment has been shown to reduce muscle wasting
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in non-small cell lung cancer patients [153]. A unique peptide-based strategy, OHR188,
targeting of both TNF-α and IL-6 also has demonstrated effectiveness in improving body
weight, select physical activities, and appetite [154]. Surprisingly, physical therapy has
been shown to be anti-inflammatory, improves body composition and function, and even
has survival benefits for cancer cachexia patients [136, 155-157].
Single-agent or mono-strategy treatments are not effective for cancer cachexia
due to the complexity of the disease. Multi-modal strategies will be needed to address all
the diverse pathophysiological mechanisms of the disease. A Phase III trial focusing on a
multi-modal therapy, called the MENAC (Multimodal- Exercise, Nutrition, and Antiinflammatory medication for Cachexia) trial, is currently underway to the efficacy of
addressing many of the contributors to cancer cachexia [158, 159]. If successful, the study
will provide not only a new approach but the first stand-of-care treatment for cancer
cachexia.

Chapter 2: Materials and Methods
Cell Culture
All cells were cultured at 37 °C in a humidified cell culture incubator with 5% CO2.
S2-013 pancreatic cancer cells were obtained from Dr. Michael A. Hollingsworth [160].
The HCC cell line PLC/PRF/5 was obtained from ATCC. Pancreatic and hepatocellular
carcinoma cells were cultured in Dulbecco’s Modified Eagle Medium (DMEM) with 10%
fetal bovine serum (FBS), 100 I.U./mL penicillin, and 100 μg/ml streptomycin. C2C12
myoblasts were acquired from American Type Culture Collection (ATCC) and cultured in
DMEM with 20% FBS, 100 I.U./mL penicillin, and 100 μg/ml streptomycin. Myoblasts were
cultured until near confluency and then differentiated with DMEM with 2% horse serum
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and 1 µg/ml insulin for 72 hours, as previously described [161]. SP600125 was purchased
from LC Laboratories (MA, USA) and dissolved in dimethyl sulfoxide (DMSO).

Cancer Cell-Condition Media Preparation
S2-013 pancreatic cancer cells were cultured to 80% confluency, as previously
described [161]. At which point, the cancer cells were rinsed twice with 1X phosphatebuffered saline (PBS) and cultured in serum-free DMEM for 24 hours. CM was then
collected and centrifuged at 3,000 RPM for 10 minutes, sterile syringe-filtered, and used
immediately or frozen at -80 °C for long term storage. Both conditioned media (CM) and
control DMEM were supplemented with 2% HS for experiments.

Cell Proliferation and Viability Assays
Evaluation of cell proliferation for HCC cancer cells was completed by a Nexcelom
Celigo Imaging Cytometer (Lawrence, MA) to determine culture plate confluence. Cell
viability was evaluated by the Promega CellTiter-Glo Luminescent Cell Viability Assay
(Madison, WI) per manufacture protocols. Colony formation assays were performed by
plating 2500 cells in a 12 well plate; colonies were stained and imaged 14 days later using
0.2% crystal violet in 80% methanol.

Protein Isolation and Immunoblotting
Protein isolation and immunoblotting were performed as described previously
[162]. In brief, cells were rinsed twice with 1X PBS, shaken on ice for ten minutes with
radio-immunoprecipitation assay (RIPA) lysis buffer supplemented with a cocktail of
phosphatase inhibitors (10 mM sodium fluoride, 2 mM sodium orthovanadate, and 2 mM
disodium beta-glycerophosphate) to lyse. Cell lysates were centrifuged at 13,000 RPM for
5 minutes and the resulting supernatant collected. Equal protein amounts for each sample
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were separated by SDS-PAGE and transferred onto a nitrocellulose membrane. Primary
antibodies against JNK, p-JNK, c-Jun, p-Jun, c-Myc, ME2, mTOR, p-mTOR, p70S6K, pp70S6K, AKT, p-AKT, and CIP2A were obtained from Cell Signaling Technology
(Danvers, MA). MuRF1/Trim63, Atrogin-1/Fbox32 were purchased from Santa Cruz
Biotechnology (Dallas, TX, USA). MyHC and beta-actin primary antibodies were obtained
from Developmental Studies Hybridoma Bank (Iowa City, IA, USA). Beta-actin was used
as a loading control. All primary antibodies were used at a dilution of 1:1000.

RNA Isolation qRT-PCR
Total RNA was isolated from cells or tissue homogenates with TRIzol reagent
(Invitrogen, Carlsbad, USA) according to the manufacturer’s protocol. Complementary
DNA (cDNA) was prepared with the use of a High-Capacity cDNA Reverse Transcription
Kit (Applied Biosystems, NY, USA). qRT-PCR was executed using SYBR Green PCR
Master Mix (Applied Biosystems, NY, USA). Primers for ACTB were used for an internal
control. As described previously, relative gene expression analysis was completed via the
∆∆Ct method [163]

Luciferase Reporter Assay
A Firefly Luciferase Reporter Assay (Promega, Madison, Wisconsin), per
manufacturer’s protocols, was used to detect the expression status of c-Myc using the cMyc Del1 and 4x-TBE constructs (Addgene, Watertown, Massachusetts) [164].

Reverse Phase Protein Array
A phospho Explorer Antibody Microarray (Full Moon BioSystems, CA, USA) was
used as per the manufacturer’s instructions. In brief, cell lysates were isolated using
Protein Extraction Buffer (Full Moon BioSystems). After biotin labeling, the samples were
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applied to pre-blocked microarray slides and washed. Protein signal was detected using
Cy3-conjugated streptavidin. Signal intensities were normalized to the average intensity
of the total spots on the array, and the average median signal was used for further
analysis.

Metabolomics
Polar metabolites were extracted from cells seeded in 10 cm plates and then
analyzed with liquid chromatography-tandem mass spectrometry (LC-MS/MS) using the
selected reaction monitoring (SRM) method utilizing positive and negative ion polarity
switching on a Xevo TQ-S mass spectrometer [165, 166]. Peak areas integrated using
Skyline 20.2 (www.skyline.ms) were normalized to the respective DNA concentrations of
samples, and the normalized peak areas were compared using relative quantification
analyses by employing Metaboanalyst 4.0 (www.metaboanalyst.ca) [167, 168]. Metabolic
pathway analysis and partial least squares discriminant analysis (PLC-DA) were also
assessed via Metaboanalyst 4.0.

Orthotopic Xenograft Implantation Model of Pancreatic Cancer
Six- to eight-week-old female athymic nude mice (NCr-nu/nu) were injected with
2.5×105 S2-013 pancreatic cancer cells into the pancreas. Age- and gender-matched
healthy mice not implanted with cancer cells were used as controls. The JNK inhibitor,
SP600125, was dissolved in DMSO. Ten days after orthotopic implantation, mice received
IP injection of 10 mg/kg of SP600125 five days a week or DMSO. Body weight and tumor
volumes estimated by caliper were recorded regularly. 27 days after orthotopic
implantation, the mice were euthanized and necropsied. Body weight, carcass weight,
tumor weight, tumor volume, and gastrocnemius muscle weight were recorded as
previously described [161]. Organs and tumor tissue were isolated, flash-frozen in liquid
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nitrogen or formalin-fixed. Outliers determined by a Grubb’s test (α = .05) were removed
(GraphPad, CA, USA). Muscles were fixed in methacarn (60% methanol, 30% chloroform,
and 10% glacial acetic acid). All animal experiments were approved by the University of
Nebraska Medical Center Institutional Animal Care and Use Committee (IACUC).

Measurement of Grip Strength and Rotarod Test
This study utilized a grip strength meter (Columbus Instruments, OH, USA) to
assess mice forelimb grip strength, as previously described [161]. Latency to fall, or
rotarod performance, was determined with a rotarod apparatus (Rotamex-5, Columbus
Instruments, OH, USA), as previously described [161]. Mice were acclimated to the
procedure room for 15 minutes prior to rotarod testing. The average of three technical
replicates was used for each mouse at each time-point.

Immunohistochemistry
Immunohistochemistry was completed by employing Novolink Polymer (Leica,
Wetzlar, Germany) according to the manufacturer’s instructions. c-Jun, ME2, and Ki67
antibodies were purchased from Cell Signaling Technology (Danvers, MA); c-Myc
antibody was obtained from Santa Cruz Biotechnology (Dallas, Texas). The stained
sections were imaged at 200X with a DMI6000 Leica microscope. Muscle fibers with cJun staining were counted in three random fields at 200X magnification from three
biological replicates. The intensity score was generated by evaluating staining intensity of
positive staining (0 = none, 1 = weak, 2 = intermediate, 3 = strong). The overall c-Jun
protein expression in each sample is expressed as a composite score, which is the
multiplication product of the intensity score (0 – 3) by the percentage of stained fibers (100
x fibers in each intensity score divided by the total number of fibers). Ki-67 positive nuclei
rate in HCC cells was generated by counting the proportion of Ki-67 positive cells to total
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cells in three random fields per sample. Image J 1.5 was used to measure the muscle fiber
cross-sectional area [169].

Bioinformatics
The HCC patient transcriptomic data used here are based upon data generated by
The Cancer Genome Atlas (TCGA) Research Network (www.cancergenome.nih.gov/).
TCGA clinical files, mRNA, and copy number were downloaded using the TCGA Data
Matrix on 12/3/20. Tailored regular expressions were generated for clinical patient files,
and the information was collated in a master spreadsheet for all further assessment. If
analyses segregated patients based on copy number alterations or tumor stage, patients
with unclear copy number alterations or American Joint Committee on Cancer (AJCC)
tumor staging were removed from their respective analyses. Tumor stages were
segregated only by their numerical AJCC value. Patient files that contained information
for both last follow up and days to death were assessed by their days to death data. All
data analyses were performed with Perl5 version 16.3 (www.perl.org) and statistical
calculations were performed in R version 3.1.3 (www.r-project.org) [170].

Diethylnitrosamine

Chemically-induced

Mouse

Model

of

Hepatocellular Carcinoma
Male, two-week-old mice (C57BL/6) were intraperitoneally (IP) injected with 75
mg/kg of diethylnitrosamine (DEN) to chemically induce HCC, and mice were sacrificed
eight months later [171]. Speer6 (albumin)-Cre-/- mice were obtained from the Jackson
Laboratory (Bar Harbour, ME) and ME-/- from Helmholtz Zentrum Muenchen (Neuherburg,
Germany); the mice were bred to generate the genotypes Speer6-Cre-/-; ME2flox/flox,
Speer6-Cretg/+; ME2flox/WT, and Speer6-Cretg/+; ME2flox/flox. Organs and tumor tissue were
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isolated, flash-frozen in liquid nitrogen or formalin-fixed. All animal experiments were
approved by the University of Nebraska Medical Center IACUC.

Statistical Analysis
One-way ANOVA with Tukey’s post hoc test was utilized to compare differences
between multiple groups. Student’s t-test was used when appropriate for comparisons
between two groups. Patient survival was compared using the log-rank test and univariate
Cox-proportional hazard regressions were used to evaluate the association between log2
scaled mRNA expression levels with the survival of each patient in each cohort [172]. All
tests were performed using GraphPad Prism 8. For all experiments, α = 0.05 was used
for significance and probability is indicated by: *p < 0.05, **p < 0.01, ***p < 0.001.
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Chapter 3: The Role of Malic Enzyme 2 in Hepatocellular
Carcinoma
Introduction
Hepatocellular carcinoma is an enigmatic malignancy that commonly occurs
throughout the world. Its rate of occurrence has drastically increased over the past
decades in the United States due to hepatitis infections and increasing levels of metabolic
disease [4-6]. HCC incidence and survival rates widely vary across the globe. SubSaharan African nations and East Asian countries are particularly devastated by the
disease, accounting for as much as 80% of all cases [1, 173, 174]. These countries have
higher levels of environmental risk factors, inadequate HCC surveillance, and substandard
treatment accessibility. However, even in Europe and North America, more than 60% of
patients present with intermediate or advanced disease [175]. As with most solid cancers,
surgical resection or liver transplantation offer the greatest chance for survival but is only
available to early disease. Intermediate staged HCC is often addressed by TACE, while
the standard-of-care for advanced disease are systemic multi-kinase chemotherapies like
Sorafenib or Lenvatinib [3, 7, 37].
Metabolic reprogramming is a hallmark of cancer and HCC specimens display
many of the canonical alterations. One of the most notorious metabolic modifications, the
Warburg Effect, is characterized by an increased level of glucose uptake and reliance on
aerobic glycolysis [176-180]. To support this demand in HCC there often is an upregulation
of levels of the glucose transporters, GLUT1 and GLUT2, to support elevated
requirements for glucose and an enhanced reliance on glycolysis [180-186]. Elevated
glycolysis is also provoked by the upregulation of several enzymes in the pathway
including hexose kinase (HK) 2 or HK domain containing 1 (HKDC1), glyceraldehyde 3-
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phosphate dehydrogenase (GADPH), and pyruvate kinase M2 (PKM2) [187-192].
Conversely, there is a shift away from mitochondrial metabolism, partly due to elevated
lactate dehydrogenase A (LDHA) levels, which converts pyruvate to lactate and diverts
substrate from the TCA Cycle [193, 194]. Like many cancers, HCC specimens are
addicted to glutamine, and they particularly rely on glutaminolysis for TCA anaplerosis
[195-198]. While glutamine addiction is a prominent amino acid metabolic alteration, there
is generally an upregulation of overall amino acid metabolism and production which is
believed to be a byproduct of increased glucose flux [196, 199-204]. Altered catabolic and
anabolic lipid metabolism also occurs in HCC. Fatty acid oxidation has been shown to be
both increased and decreased in HCC with variations observable in different metabolic
subtypes, while most display excessive de novo lipid synthesis [205, 206]. De novo
lipogenesis requires NADPH and HCC tumors have been shown to upregulated pathways
that produce the reducing equivalent [197]. The reducing power of NADPH is also a key
component for antioxidant defense against reactive oxygen species (ROS) in cancer cells.
HCC cells demonstrate elevated glutathione (GSH) synthesis due to elevated amino acid
pools, and increased NADPH is important for the regeneration of the oxidized glutathione
dimer (GSSG) back to GSH [207]. Overall, HCC specimens display a host of metabolic
alterations to support their increased biosynthetic demands.
Malic enzymes are major generators of necessary reducing equivalents of NADPH
[199]. These enzymes are oxidative carboxylases that concomitantly produce pyruvate
and NADPH or NADH [208, 209]. There are three mammalian malic enzyme isoforms that
differ in cellular localization and substrate specificity; the cytosolic malic enzyme 1 (ME1)
and mitochondrial malic enzyme 3 (ME3) are NADP+-dependent [210]. Malic enzyme 2
(ME2) is also mitochondrially located, but the enzyme is unique in that it is promiscuous
and able to utilize either NADH+ or NAD+ as substrate [211]. Malic enzymes are homo-
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tetrameric proteins that form from a dimer of dimers [212]. Its activity is regulated by
substrate availability as well as by modulators; NAD+ and fumarate activate the enzyme,
while ATP and ADP are known to inhibit its activity [213]. NAD+ binding promotes the
formation of tetramers which exhibit more activity, and conversely ATP is known to
stimulate separation into dimers [213].
ME2 has influential roles in a variety of cancers [208, 214-219]. Expression of
ME2 has been shown to promote cancer proliferation [208, 215-218]. Additionally,
expression of the carboxylase contributes to cancer migration and invasion [208, 217].
ME2 has been demonstrated to induce cellular differentiation [215, 216]. ME2 also
generates pyruvate to support TCA Cycle metabolism in low glucose conditions [220]. Due
to the enzymatic activity of the ME2, it is logical that the depletion of enzyme perturbs
oxidative phosphorylation [215, 216, 218]. However, ME2 expression also elevates
glutaminolysis in part via a p53-mediated and reciprocal positive-feedback loop [214, 218].
The reducing potential of NADPH is utilized in biosynthetic processes such as de novo
lipogenesis as well as is important for redox homeostasis [221]. Altered fatty acid
production is also associated with increased ME2 levels in HCC as specimens have been
shown to upregulate malic enzymes to generate needed NADPH [197, 199]. ME2 is an
important metabolic enzyme in a host of malignancies; however, the role of the enzyme in
HCC is not fully understood. In these studies, we aimed to evaluate if ME2 regulates HCC
progression.

Results
Elevated ME2 Expression Impacts HCC Patient Survival
To investigate if ME2 expression impacts HCC patient survival, we examined
patients with the upper (ME2 High) and lower (ME2 Low) quartile of ME2 expression from

23
HCC patients in The Cancer Genome Atlas (TCGA) (Figure 1A) [222]. When the overall
survival between the ME2 High and ME2 Low groups is compared, there is a significantly
shorter median survival for ME2 High patients (Figure 1B). There is a slight trend of
increased expression of ME2 when all the HCC patients in the TCGA when their American
Joint Committee on Cancer (AJCC) tumor staging increases, but these changes were not
statistically significant (Figure 2). These data suggest that elevated ME2 expression
corresponds with poorer median survival for HCC patients.
To better understand what underlies the survival differences between the ME2
High and ME2 Low groups, we inspected the transcriptomic data of the patients. Gene set
enrichment analyses were completed using multiple gene sets and databases to garner a
broader perspective. The Molecular Signatures Database (MSigDB) Hallmarks gene set
revealed that c-Myc targets, multiple metabolic pathways, reactive oxygen species
pathway, and PI3K/AKT/mTOR signaling as some of the most enriched gene sets in the
ME2 High patient group (Figure 3). The Gene Ontology (GO) gene set identified
transcription and translation-related pathways and several metabolic pathways such as
central carbon and oxidoreductive metabolism (Figure 4). The Kyoto Encyclopedia of
Genes and Genomes (KEGG) gene set also highlighted an enrichment in ribosomal gene
sets as well as central carbon and redox-related pathways (Figure 5). Overall, these data
suggest an enrichment in c-Myc activity, PI3K/AKT/mTOR signaling, and alterations to
central carbon and redox metabolism in tumors expressing high levels of ME2.
Univariate cox-proportional hazard regression was used to evaluate the
association of log2 scaled mRNA expression with the survival of HCC patients between
the ME2 High and ME2 Low groups (Figure 6). To further refine which genes not only
impact survival but also could be targetable due to elevated expression, we evaluated the
genes with the highest fold-change increase in the ME2 High patient group with a hazard
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ratio greater than 2.75 (Figure 7). Notably, KIAA1524, also known as Cancerous Inhibitor
of PP2A (CIP2A), was one of the most highly over-expressed genes; CIP2A is a molecule
known to directly associate with the c-Myc protein and prevents c-Myc proteolytic
degradation by disrupting the phosphatase activity of PP2A [223]. Additionally, SLC2A1,
also known as GLUT1 and a known target of c-Myc, demonstrated a more than two-fold
over-expression in the ME2 High cohort; which could support the carbon flux in many of
the metabolic pathways observed in the gene set enrichment analyses [185, 224]. These
data suggest that activation of the c-Myc pathway may underlie the metabolic pathway
enrichment and survival differences observed in patients with elevated ME2 expression.

ME2 Copy Number Alterations Impact Expression and Stagedependent Patient Survival
Copy number alterations can have a substantial impact on gene expression, so we
examined all the HCC patients in the TCGA for how copy number alterations in ME2
impacted the expression of malic enzymes. Copy number gain in ME2 correlated with a
significant increase in ME2 expression in comparison to diploid tumors, and conversely
tumors with heterozygous loss (shallow deletion) of ME2 significantly reduced its mRNA
expression (Figure 8A). Only one patient was found to have homozygous deletion in ME2.
We examined the expression of the malic enzyme isoforms ME1 and ME3 to assess
whether there is any compensation when the ME2 copy number changed. We found that
regardless of the copy number status of ME2, there are no significant changes to the
expressions of ME1 or ME3 (Figure 8B and C).
Next, we evaluated the survival of HCC patients segregated by their ME2 copy
number alterations to investigate whether it corresponded to a differential survival
outcome. When we examined survival for all the HCC patients in the TCGA, we observed
no statistical difference in median survival between patients based on their ME2 copy
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number alteration status (Figure 9A). We then segregated the patients based on their
AJCC tumors staging and again evaluated survival. HCC patients with AJCC tumor
staging of T1 exhibited no survival differences based on ME2 copy number alterations
(Figure 9B). However, when patients with AJCC tumor staging of T2 are evaluated,
patients with heterozygous ME2 copy number loss display longer median survival than
patients with ME2 copy number gains (Figure 9C). Unexpectedly, when confining survival
analyses to the patients with AJCC tumor staging of T3, the patients with heterozygous
ME2 copy number exhibit a much poorer median survival which is only significantly shorter
when compared with patients with diploid ME2 tumor status (Figure 9D). The disparity in
median survival patterns between T2 and T3 staged tumors may reflect a differential role
of ME2 during tumor progression or could also be confounded by additional mutations
obtained in later staged tumors [225, 226]. However, it can be surmised that ME2 copy
number alterations impact its expression not the other malic enzymes, and that ME2 copy
number alterations correspond with some stage-dependent survival differences.

ME2 Expression Supports HCC Growth In vitro
To examine the role of ME2 in an in vitro model of HCC, we knocked-out (KO) ME2
in the HCC cell line PLC/PRF using CRISPR-Cas9 in two independent regions of the gene
(sgME2) and utilized a scramble construct as a control (sgScr); sgME2 clones sgME2 12 and sgME2 2-3 will herein be referred to sgME2-1 and sgME2-2, respectively (Figure
10A). Longitudinal evaluation of proliferation via cell confluency demonstrated that the loss
of ME2 reduced the proliferation of the PLC cells as compared to either the sgScr control
or wild-type (WT) cells in normoxic culture conditions (Figure 10B). These growth
differences may be exacerbated under hypoxic conditions (72 hours) as ME2-KO cells
display an even more substantial loss in viability (Figure 10C). Additionally, a colony
formation assay further supported these data by demonstrating that sgME2 cells exhibit
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diminished clonogenicity (Figure 11A and B). Overall, these data suggest that ME2 is protumorigenic in HCC and that ME2 expression supports cell viability in an in vitro model.

ME2 Expressing HCC Cells Exhibit Elevated C-Myc Levels and mTOR
Signaling
To connect our bioinformatic patient data to our in vitro HCC model, we examined
some of the notably enriched pathways and altered genes in our PLC-KO cells. The
MSigDB Hallmarks gene set identified the c-Myc pathway as the most enriched gene set
and we also discovered that CIP2A was the most elevated gene in the ME2 High cohort
of the genes with a high Hazard Ratio, so we examined their protein levels. We found that
loss of ME2 correlated with reduced c-Myc and CIP2A levels (Figure 12). To further
disseminate the positive correlation of ME2 and c-Myc expression, we completed a c-Myc
luciferase reporter assay with two different constructs and found that the loss of ME2
significantly decreases the observed luminescence (Figure 13A and B) [164, 227]. Due to
the enrichment of PI3K/AKT/mTOR signaling in ME2 High patients and known
connections with and ME2, we also evaluated their protein levels [215, 216]. We found
that the loss of ME2 correlated with a reduction in p-mTOR and diminished the
phosphorylation of its targets AKT and p-p70 (also known as p70 S6 kinase) (Figure 14).
We treated our cells with Everolimus (5 μM), a rapamycin analog, for 72 hours to target
mTOR and evaluated viability; the treatment was significantly effective in reducing viability
in both sgScr and sgME2 cells (Figure 15). However, there was no substantial differential
sensitivity based on ME2 status. Overall, these data suggest that ME2 expression in our
in vitro model supports elevated c-Myc levels as well as leads to increased
PI3K/AKT/mTOR signaling.
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ME2 Expression Supports Central Carbon and Redox Metabolism In
Vitro
To examine the metabolic function of ME2 in our in vitro model, we completed
polar metabolomics. We performed polar metabolite isolation and executed targeted liquid
chromatography-tandem mass spectrometry (LC-MS/MS) (Figure 16). Employing a partial
least squares discriminant analysis (PLS-DA) to differentiate the samples based on their
total polar metabolite pools, we observed cluster separation between our samples in the
principal component (PC) 1 and PC2 (Figure 17). Among the most diminished metabolites
in sgME2 cells were glycolytic and TCA intermediates as well as both NADPH and NADH
(Figure 18). We performed quantitative enrichment analysis and observed notable
enrichment to aspartate metabolism, central carbon metabolism, and the reactive oxygen
species mitigating glutathione metabolism (Figure 19). Additionally, we performed
pathway analysis and it demonstrated similar results which highlighted the malateaspartate shuttle, amino acid pathways, and central carbon metabolism pathways as
among the most greatly impacted (Figure 20). Evaluation of glycolytic intermediates
revealed an overall significant reduction in most of the metabolites in the pathway when
ME2 was depleted (Figures 21A-G). Similarly, almost all the observed TCA Cycle
intermediates displayed significantly reduced levels in sgME2 cells (Figures 22A-G).
These data suggest there is augmented central carbon metabolism, which may
correspond to elevated GLUT1 levels in patients with high expression of ME2.
Due to the importance of ME2-generated reducing equivalents as well as the
enrichment of glutathione and redox metabolism in the ME2 High patient cohort, we
examined the glutathione metabolism pathway metabolites from our LC-MS/MS
spectrometric analysis. Reduced glutathione (GSH) levels and the amino acids that
comprise the tripeptide were significantly diminished in sgME2 cells (Figures 23A-D). Most
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other amino acids displayed a similar significant reduction in ME2 depleted cells (Figures
24A-H). Additionally, the ratio of GSH to oxidized glutathione (GSSG) was reduced in one
of the sgME2 clones (Figure 23E). However, there was a striking significant increase in
both NADP+ to NADPH and NAD+ to NADH ratios in sgME2 cells (Figures 24F and G).
The reducing potential of NADPH is required for biosynthetic processes like de novo
lipogenesis; while our polar metabolite extraction is not optimized to enrich lipid species
for LC-MS/MS detection, we could detect acylcarnitines. The overall trend was a
significant reduction in acylcarnitine levels, except for the longest acylcarnitine C18 in
which one sgME2 clone demonstrated significantly increased levels (Figures 25A-H).
These data suggest the expression of ME2 supports glutathione metabolism and amino
acid metabolism, and that there may be underlying lipid metabolism alterations.

ME2 Expression Supports Tumor Formation in Diethylnitrosamine
Chemically-induced Mouse Model of HCC
To expand the pro-tumorigenic role for ME2 beyond our patient bioinformatic and
in vitro data into a higher-order model, we examined the role of ME2 in a chemicallyinduced mouse model of HCC. We employed a widely utilized diethylnitrosamine (DEN)
chemically-induced mouse model in the immune-competent C57BL/6 strain using Speer6
(albumin)-Cre-/-; ME2flox/flox, Speer6-Cretg/+; ME2WT/flox, and Speer6-Cretg/+; ME2flox/flox [228].
Male mice were injected with a single IP injection of DEN (75 mg/kg) at two weeks of age
and sacrificed after eight months [229]. Macroscopic lesions were observed upon
necropsy, and heterozygous or homozygous loss of ME2 in mice livers led to significantly
reduced tumors (Figure 26A). A reduction in neoplasia was also suggested by a significant
reduction in liver to body weight ratio in mice with the heterozygous or homozygous loss
of ME2 (Figure 26B). Immunohistochemistry of the tumor tissues indicates that control
Speer6-Cre-/-; ME2flox/flox mice exhibit elevated ME2 expression, levels of the proliferative
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marker Ki67, and amount of the transcription factor c-Myc in comparison to Speer6-Cretg/+;
ME2WT/flox and Speer6-Cretg/+; ME2flox/flox mice (Figure 27A and B). These data continue to
support that expression of ME2 increases HCC initiation and proliferation, and that
increased c-Myc levels may underlie some of these observations.

Discussion and Future Directions
HCC is a devastating malignancy and is responsible for the second most cancer
deaths worldwide [1, 5]. Tumors from HCC patients display a multitude of metabolic
alterations to support the proliferative growth of the malignant cells [177, 230-232]. We
identified that elevated levels of the mitochondrial oxidative carboxylase, ME2, correlates
with significantly reduced HCC patient survival in a TCGA dataset. To understand the
underlying differences between HCC patients with high and low ME2 levels, we assessed
the transcriptomic data of the patient cohorts. ME2 High patients display enrichments in
the c-Myc and PI3K/AKT/mTOR pathways. The master regulator c-Myc is overexpressed
in up to 70% HCC, elevated levels predict shorter survival prognosis, and high levels
associated with metastatic and recurrent tumors [233-237]. Enrichment in the c-Myc
pathway may be the result of the increased expression of CIP2A observed in the ME2
High cohort, which is a molecule that stabilizes c-Myc protein levels by preventing posttranslational modifications that lead to proteasomal degradation [223]. PI3K/AKT/mTOR
signaling pathway is the most frequently activated in cancer and more than half of HCC
patients display activation [238]. PI3K/AKT/mTOR signaling in HCC correlates with more
aggressive tumor progression, shorter survival, and increased recurrence after surgery
[239-242]. The depletion of ME2 has previously been shown to impair PI3K/AKT/mTOR
signaling in multiple cancers [215, 216]. Additionally, there were enrichments in metabolic
pathways associated with central carbon, fatty acid, amino acid, and reactive oxygen
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species metabolism. Elevated c-Myc and PI3K/AKT/mTOR signaling have been shown
to induce these metabolic alterations in cancer [221, 243].
Since copy number alterations can have a tremendous impact on gene expression,
we evaluated how ME2 genomic alterations influence the expression of malic enzymes.
We identified that that copy number correlated with ME2 expression in HCC patients from
the TCGA, but ME2 copy number had no impact on ME1 or ME3 levels suggesting no
compensation by expression of these isoforms. Intriguingly, examining all the HCC
patients in the TCGA based on their ME2 copy number alterations yielded no significant
survival differences, but segregating them into their AJCC tumor stages revealed some
variances. Of the patients with T2 AJCC tumor classification, those with heterozygous
deletion of ME2 exhibited the longest median survival but patients with copy number gains
trended towards poorer survival. Conversely, when only patients with T3 AJCC tumor
staging were examined, patients with a heterozygous deletion in ME2 experienced
significantly shorter survival than patients with diploid status. These results may indicate
that there are some stage-specific roles for ME2, that ME2 expression could be regulated
via a mechanism other than copy number alteration in most HCC patients, or that
additional mutational burden may influence survival.
In our in vitro HCC cell culture model, the expression of ME2 proved to be consistent
with the pro-tumorigenic role observed in several cancers [215, 216]. The depletion of
ME2 led to reduced proliferation and clonogenicity. Small molecule inhibition of ME2 with
NPD389 or embonic acid could reveal if chemical inhibition of ME2 generates similar
growth inhibition to genetic perturbation and thus legitimizes directly targeting ME2 as a
therapeutic for HCC [244, 245]. Similarly, in our in vivo chemically-induced model of HCC,
ME2 expression also supported tumor formation and a marker of proliferation. Further
experimentation is needed to evaluate if ME2 expression impacts invasion and migration
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in HCC like other cancers, which could be assessed in vitro by wound closure and
transwell assays or in vivo via the use of a metastatic mouse model HCC [208, 217, 246].
Observed enrichment in the c-Myc pathway from our bioinformatic data was corroborated
by diminished protein levels of c-Myc and its regulator, CIP2A, in ME2 depleted cells. Coimmunoprecipitation, immunofluorescent co-localization, or other protein-to-protein
interaction methodologies should be performed to suggest if the proteins indeed interact;
while depletion of CIP2A could reveal if the protein is contributing to c-Myc stabilization in
our model. Initial evaluation of immunohistochemistry of our mouse liver tissues also
suggests that c-Myc is also elevated in mice with ME2 expression. Depletion of c-Myc is
needed to dissect if there is a reciprocal regulation of ME2, like the feed-forward
mechanism between p53 and ME2 [218].
Observed enrichment in PI3K/AKT/mTOR signaling in our ME2 High cohort was
consistent with the elevated activation of the pathway in our ME2 competent cells. CIP2A
has also been shown to stymie PP2A-dependent dephosphorylation of AKT and
mTORC1, thus sustaining their signaling capacity; therefore, CIP2A could directly
influence the activation of both the c-Myc and PI3K/AKT/mTOR pathways [247-250]. We
tested the efficacy of the mTOR inhibitor, Everolimus, in our PLC-KO cells to see if there
is differential sensitivity based on ME2 expression. While Everolimus treatment
significantly diminished viability in all cells, it did not do so disproportionately in the cells
with ME2 expression. Liver cancer cells with c-Myc deregulation have been shown to
demonstrate resistance to mTOR inhibition [251]. Also, monotherapy in patients is not
sufficient on its own, so combination treatment with other PI3K/AKT/mTOR inhibitors may
reveal differential sensitivity [252]. Another prospective treatment for HCC with elevated
ME2 levels could be the flavonoid quercetin or its derivatives; the drug has been shown
to concomitantly decrease c-Myc levels along with PI3K/AKT/mTOR signaling, and it
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disrupts glycolysis by targeting GLUT1 and decreasing HK2 levels [253-255].
Alternatively, inhibitors of ME2 could be explored to indirectly disrupt PI3K/AKT/mTOR
and c-Myc signaling for a therapeutic targeting of tumors dependent on ME2.
Due to the enzymatic activity of ME2, we completed LC-MS/MS analysis to
evaluate the metabolic impact of ME2 expression in our HCC cell line model. Metabolite
and pathway enrichment identified similar metabolic alterations observed from our patient
dataset. Central carbon, amino acid, antioxidant, and fatty acid metabolism were enriched
in ME2 expressing cells. Elevated glycolysis in HCC has been shown to associate with
poorer patient prognosis as well as resistance to Sorafenib treatment [256, 257]. While
our polar metabolite extraction method is not amendable to lipidomics, we could detect
acylcarnitines. Acylcarnitines are esters between fatty acids and L-carnitine and they have
a primary function of transporting fatty acids into the mitochondria for fatty acid oxidation
[258, 259]. Elevated acylcarnitine levels in ME2 expressing cells could indicate
suppression fatty acid oxidation, which enhances hepatocellular carcinogenesis and
stimulates the stem cell-like properties or elevated contributions of lipids to mitochondrial
acetyl-coenzyme A pools [260]. However, to confirm the metabolic impact of ME2
expression in our model, further experiments could be done as steady-state LC-MS/MS
only gives a snapshot of the metabolism in cells at a particular time. Mass spectrometry
utilizing carbon-13 (13C) labeled substrate (glucose, glutamine, and palmitate) could permit
the identification of the metabolic flux through glycolysis, TCA Cycle metabolism, and fatty
acid metabolism. Examination of the impact of ME2 expression on anaplerotic
glutaminolysis in our model is a vital interest via this technique. While the determination
of oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) using an
Agilent Seahorse XF Analyzer could evaluate the glycolytic rate, respiratory capacity, and
dependency on substrate utilization [261, 262]. Additionally, we would also like to evaluate
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if ME2 expression alters metabolism by impacting glucose and glutamine consumption via
uptake assays [263, 264].
An interplay between PI3K/AKT/mTOR and c-Myc could explain much of the
metabolic differences that were identified when combined with the functions of ME2.
These two pathways can stimulate each other as PI3K/AKT/mTOR increases c-Myc via
an amalgamation of transcriptional, translational, and post-translational means [265-270].
While c-Myc can activate mTOR via the upregulation of amino acid transporters [268-271].
ME2 expression in several cancers supports PI3K/AKT/mTOR signaling [215, 216].
Additionally, PI3K/AKT/mTOR signaling increases glucose uptake as well as boosts
glycolysis by increasing the activity of HK2 [272, 273]. C-Myc also supports glycolysis by
increasing the expression of GLUT1 and HK2 as well as transactivation of LDHA [274276]. C-Myc-driven hepatic tumors increase glutaminase activity with a switch from livertype glutaminase (GLS2) to kidney-type glutaminase (GLS1) and they elevate the
expression of the glutamine transporter SLC1A5, which could support increased glutamine
dependency and glutaminolysis in our system [218, 277]. ME2 metabolism is significant
for antioxidant defense and lipid metabolism as it generates NADPH reducing equivalents,
and previous studies demonstrate cancers upregulate malic enzymes to support these
processes [197, 278]. PI3K/AKT/mTOR signaling is also involved in lipid metabolism via
direct phosphorylation of lipid metabolism enzymes or via stimulation of the sterol
regulatory element-binding protein (SREBP) family of transcription factors which
subsequently enhance the expression of fatty acid metabolism enzymes [279-282].
Overall, this work expounds upon previous work demonstrating a pro-tumorigenic
role of ME2 in numerous cancers and expands it into HCC. These data indicate that ME2
expression correlates with poor patient prognosis and increased cancer proliferation in our
in vitro and mouse models. Additionally, these data highlight the enrichment in c-Myc and
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PI3K/AKT/mTOR pathways in ME2 expressing cells and patients, which correlate with the
metabolic alterations emblematic of these pathways. This work identifies the novel role of
ME2 in HCC, and potentially elucidates potential mechanisms to exploit HCC with high
ME2 levels via targeting signaling and metabolic pathways.
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Figures
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Figure 1. Elevated ME2 expression reduces HCC patient survival. HCC patients from
the TCGA were segregated based on their malic enzyme 2 (ME2) expression. The upper
and lower quartile were categorized as ME2 High and ME2 Low (n=90, each),
respectively, and their (A) ME2 mRNA expression and (B) and Kaplan-Meier survival plot
were plotted. Data in (A) were presented as mean ± SEM and compared using a Student’s
t-test, and the median survival data in (B) were compared using a log-rank test. **p<0.01
and ***p<0.001.
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Figure 2. ME2 expression with HCC tumor stage. HCC patients from the TCGA were
segregated based on their American Joint Committee on Cancer (AJCC) tumor stage and
their ME2 mRNA expression were plotted (T1, n=180; T2, n=93; T3, n=80; T4, n=14). Data
were presented as mean ± SEM and compared by one-way ANOVA followed by Tukey’s
post hoc test.
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Figure 3. Enriched pathways from the Molecular Signatures Database (MSigDB)
Hallmarks gene set in HCC patients highly expressing ME2. Gene set enrichment
analysis (GSEA) was completed between HCC patients in the upper and lower quartile for
ME2 expression, ME2 High and ME2 Low (n=90, each), using the MSigDB Hallmarks
gene set. The top 25 pathways with the highest normalized enrichment score (NES) that
were significantly different between the cohorts were plotted (FDR q < 0.05).
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Figure 4.

Enriched pathways from the Gene Ontology (GO) database in HCC

patients highly expressing ME2. Gene set enrichment analysis (GSEA) was completed
between HCC patients in the upper and lower quartile for ME2 expression, ME2 High and
ME2 Low (n=90, each), using the Gene Ontology (GO) database. The top 25 pathways
with the highest normalized enrichment score (NES) that were significantly different
between the cohorts were plotted (FDR q < 0.05).
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Figure 5. Enriched pathways from the Kyoto Encyclopedia of Genes and Genomes
(KEGG) database in HCC patients highly expressing ME2. Gene set enrichment
analysis (GSEA) was completed between HCC patients in the upper and lower quartile for
ME2 expression, ME2 High and ME2 Low (n=90, each), using the Kyoto Encyclopedia of
Genes and Genomes (KEGG) database. The top 25 pathways with the highest normalized
enrichment score (NES) that were significantly different between the cohorts were plotted
(FDR q < 0.05).
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Figure 6. Genes with the highest hazard ratios in HCC patients highly expressing
ME2. Cox-proportional hazard regressions were used to evaluate the association between
log2 scaled mRNA expression levels with survival between HCC patients in the upper and
lower quartile for ME2 expression; ME2 High and ME2 Low, respectively (n=90, each).
Genes with the highest 25 hazard ratios were presented as mean ± 95% CI (Wald p <
0.05).
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Figure 7. The most highly overexpressed genes with high hazard ratios in HCC
patients highly expressing ME2. Cox-proportional hazard regressions were used to
evaluate the association between log2 scaled mRNA expression levels with survival
between HCC patients in the upper and lower quartile for ME2 expression; ME2 High and
ME2 Low, respectively (n=90, each). Hazard ratios for each gene presented as mean ±
95% CI (Wald p < 0.05). A hazard ratio cut-off was set at 2.75 and highest significantly
and differentially over-expressed genes were plotted as log2(fold-change (FC)) between
the ME2 high and ME2 low cohorts (p< 0.05) along with their respective hazard ratios.
Hazard ratios were were presented as mean ± 95% CI (Wald p < 0.05).
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Figure 8. ME2 copy number alterations impact the expression of ME2 but not ME1
or ME3. HCC patients from the TCGA were segregated based on their malic enzyme 2
(ME2) copy number alterations: diploid (n=229), gain (n=27), and shallow deletion (n=90).
The mRNA expression levels for (A) ME2, (B) ME1, and (C) ME3 were plotted. Data were
presented as mean ± SEM and compared by one-way ANOVA followed by Tukey’s post
hoc test. *p<0.05 and ***p<0.001.
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Figure 9. HCC patient survival segregated by their ME2 copy number alterations
and tumor stage. HCC patients from the TCGA were segregated based on their malic
enzyme 2 (ME2) copy number alterations: diploid (0), gain (1), shallow or heterozygous
deletion (-1). (A) Kaplan-Meier survival plot for HCC patients regardless of tumor stage
(diploid (0), n=226; gain (1), n=23; shallow deletion (-1), n=88). (B) Kaplan-Meier survival
plot for HCC patients with American Joint Committee on Cancer (AJCC) tumor staging of
T1 (diploid (0), n=119; gain (1), n=9; shallow deletion (-1), n=46). (C) Kaplan-Meier
survival plot for HCC patients with AJCC tumor staging of T2 (diploid (0), n=55; gain (1),
n=6; shallow deletion (-1), n=23). (D) Kaplan-Meier survival plot for HCC patients with
AJCC tumor staging of T3 (diploid (0), n=38; gain (1), n=11; shallow deletion (-1), n=17).
Data were compared using a log-rank test. *p<0.05.
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Figure 10. ME2 expression supports HCC viability in vitro. CRISPR/Cas9-mediated
knockout of malic enzyme 2 (ME2) in PLC HCC cells was stably produced by targeting
two independent genomic regions (sgME2-1 and sgME2-2); scramble guide RNA (sgScr)
was used as a control. (A) Immunoblot analysis of ME2 from wild-type (WT), sgME2, and
sgScr PLC HCC cells. Beta actin was used as a loading control. (B) Plot of relative
confluency for WT, sgME2 1-2 (sgME2-1), and sgME2 2-3 (sgME2-2) cells over 72 hours.
(C) Relative viability of WT, sgScr, and sgME2-1 cells after 72 hours of hypoxia evaluated
by a CellTiter-Glo Luminescent Cell Viability Assay. Data in (B) and (C) were presented
as mean ± SEM and compared by one-way ANOVA followed by Tukey’s post hoc test.
***p<0.001.
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Figure 11. ME2 expression supports HCC clonogenicity. CRISPR/Cas9-mediated
knockout of malic enzyme 2 (ME2) in PLC HCC cells was stably produced by targeting
two independent genomic regions; scramble guide RNA (sgScr) was used as a control.
(A) Relative clonogenicity of PLC sgScr and sgME2 HCC cells on day 14 after plating (n=3
per group) and (B) plot of average colony numbers. Data in (B) were presented as mean
± SEM and compared by one-way ANOVA followed by Tukey’s post hoc test. ***p<0.001.
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Figure 12. Depletion of ME2 impairs C-Myc and CIP2A protein levels in HCC cells.
CRISPR/Cas9-mediated knockout of malic enzyme 2 (ME2) in PLC HCC cells was stably
produced by targeting two independent genomic regions; scramble guide RNA (sgScr)
was used as a control. Immunoblot analysis of c-Myc and CIP2A from sgME2 and sgScr
PLC HCC cells. Beta actin was used as a loading control.
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Figure 13. ME2 expression positively regulates c-Myc expression in HCC cells.
CRISPR/Cas9-mediated knockout of malic enzyme 2 (ME2) in PLC HCC cells was stably
produced by targeting two independent genomic regions; scramble guide RNA (sgScr)
was used as a control. Cells were transfected with a (A) c-Myc del1 or (B) 4x-TBE reporter
plasmid and their luciferase activity were plotted. Data were presented as mean ± SEM
and compared by one-way ANOVA followed by Tukey’s post hoc test. ***p<0.001.
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Figure 14. ME2 expression stimulates PI3K/AKT/mTOR signaling in HCC cells.
CRISPR/Cas9-mediated knockout of malic enzyme 2 (ME2) in PLC HCC cells was stably
produced by targeting two independent genomic regions; scramble guide RNA (sgScr)
was used as a control. Immunoblot analysis of ME2, p-mTOR, mTOR, p-AKT, AKT, pp70S6K (p-p70), and p70S6K (p70) from sgME2 and sgScr PLC HCC cells. Beta actin
was used as a loading control.
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Figure 15. Impact of the mTOR inhibitor, Everolimus, on HCC cells with or without
ME2 expression. CRISPR/Cas9-mediated knockout of malic enzyme 2 (ME2) in PLC
HCC cells was stably produced by targeting two independent genomic regions; scramble
guide RNA (sgScr) was used as a control. Cells were treated with 5 μM of Everolimus or
control media for 72 hours and their viability assessed. Data were presented as mean ±
SEM and were compared between cell groups by one-way ANOVA followed by Tukey’s
post hoc test or by Student’s t-test when comparisons were between treatment samples.
***p<0.001.
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Figure 16. Heatmap of polar metabolites. CRISPR/Cas9-mediated knockout of malic
enzyme 2 (ME2) in PLC HCC cells was stably produced by targeting two independent
genomic regions; scramble guide RNA (sgScr) was used as a control. Polar metabolites
were isolated from the HCC cells and quantified by liquid chromatography-tandem mass
spectrometry (LC-MS/MS). Hierarchical clustering was performed on all detected
metabolites which were plotted in the heatmap. Metaboanalyst 4.0 was used to generate
the Heatmap and perform the hierarchical clustering.
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Figure 17. ME2 expression-dependent PLS-DA differential clustering of HCC cells
based on total polar metabolite content. CRISPR/Cas9-mediated knockout of malic
enzyme 2 (ME2) in PLC HCC cells was stably produced by targeting two independent
genomic regions; scramble guide RNA (sgScr) was used as a control. Polar metabolites
were isolated from the HCC cells and quantified by liquid chromatography-tandem mass
spectrometry (LC-MS/MS). Partial least squares discriminant analysis (PLS-DA) was used
to compare cells based on their total polar metabolite content. Each circle on the plot
indicates an individual sample, and the four closely clustered circles in one color represent
the technical replicates of an individual group extracted from one cell line. The X-axis and
Y-axis of the PLS-DA plot represent the principal component (PC) 1 and PC2, which
signify the variance among the groups. Metaboanalyst 4.0 was used to perform the PLSDA analyses using mean intensities and Pareto scaling distribution.
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Figure 18. Differential metabolite levels in cells depleted of ME2. CRISPR/Cas9mediated knockout of malic enzyme 2 (ME2) in PLC HCC cells was stably produced by
targeting two independent genomic regions; scramble guide RNA (sgScr) was used as a
control. Polar metabolites were isolated from the HCC cells and quantified by liquid
chromatography-tandem mass spectrometry (LC-MS/MS). The log2(fold-change (FC))
was plotted for the polar metabolites with significantly different levels between the sgME2
and sgScr cells (p< 0.05). White and black bars represent metabolites with significant
differential expression between sgME2 and sgScr cells; white, **p<0.01; black,
***p<0.001.
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Figure 19. Metabolite enrichment between sgScr and sgME2 PLC HCC cells.
CRISPR/Cas9-mediated knockout of malic enzyme 2 (ME2) in PLC HCC cells was stably
produced by targeting two independent genomic regions; scramble guide RNA (sgScr)
was used as a control. Polar metabolites were isolated from the HCC cells and quantified
by liquid chromatography-tandem mass spectrometry (LC-MS/MS). Quantitative
enrichment analysis, using the Kyoto Encyclopedia of Genes and Genomes (KEGG)
metabolite set was employed to compare enrichment between sgScr and sgME2 cells.
Data were presented as enrichment ratio and the significance as indicated.
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Figure 20. Pathway analysis between sgScr and sgME2 PLC HCC cells.
CRISPR/Cas9-mediated knockout of malic enzyme 2 (ME2) in PLC HCC cells was stably
produced by targeting two independent genomic regions; scramble guide RNA (sgScr)
was used as a control. Polar metabolites were isolated from the HCC cells and quantified
by liquid chromatography-tandem mass spectrometry (LC-MS/MS). Pathway enrichment
analysis utilizing the Globaltest algorithm compared pathway enrichment between sgScr
and sgME2 cells based on degree centrality by utilizing the Kyoto Encyclopedia of Genes
and Genomes (KEGG) pathway library. Data were presented as pathway impact and the
significance as indicated.
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Figure 21. Loss of ME2 reduces glycolytic metabolites in HCC cells. CRISPR/Cas9mediated knockout of malic enzyme 2 (ME2) in PLC HCC cells was stably produced by
targeting two independent genomic regions; scramble guide RNA (sgScr) was used as a
control. Polar metabolites were isolated from the HCC cells and quantified by liquid
chromatography-tandem mass spectrometry (LC-MS/MS). (A-G) Plotted are the peak
intensities for metabolites in the glycolytic pathway. Data were presented as mean ± SEM
and were compared between cell groups by one-way ANOVA followed by Tukey’s post
hoc test. *p<0.05 and ***p<0.001.
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CRISPR/Cas9-mediated knockout of malic enzyme 2 (ME2) in PLC HCC cells was stably
produced by targeting two independent genomic regions; scramble guide RNA (sgScr)
was used as a control. Polar metabolites were isolated from the HCC cells and quantified
by liquid chromatography-tandem mass spectrometry (LC-MS/MS). (A-G) Plotted are the
peak intensities for metabolites in the tricarboxylic acid (TCA) cycle. Data were presented
as mean ± SEM and were compared between cell groups by one-way ANOVA followed
by Tukey’s post hoc test. **p<0.01 and ***p<0.001.

79

80
Figure 23. ME2 supports glutathione levels and the ratio of reduced to oxidized
NAD(P)H. CRISPR/Cas9-mediated knockout of malic enzyme 2 (ME2) in PLC HCC cells
was stably produced by targeting two independent genomic regions; scramble guide RNA
(sgScr) was used as a control. Polar metabolites were isolated from the HCC cells and
quantified by liquid chromatography-tandem mass spectrometry (LC-MS/MS). (A-G)
Plotted are the peak intensities for metabolites involved in the glutathione antioxidant
pathway and redox homeostasis: (A) reduced glutathione (GSH), (B) cysteine, (C)
glutamate, (D) glycine, (E) GSH to oxidized glutathione dimer (GSSG) ratio (GSH:GSSG),
(F) NADP+ to NADPH ratio (NADP+: NADPH), and (G) NAD+ to NADH ratio (NAD+:NADH).
Data were presented as mean ± SEM and were compared between cell groups by oneway ANOVA followed by Tukey’s post hoc test. *p<0.05, **p<0.01, ***p<0.001.
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Figure 24. Loss of ME2 results in reduced amino acid pools. CRISPR/Cas9-mediated
knockout of malic enzyme 2 (ME2) in PLC HCC cells was stably produced by targeting
two independent genomic regions; scramble guide RNA (sgScr) was used as a control.
Polar metabolites were isolated from the HCC cells and quantified by liquid
chromatography-tandem mass spectrometry (LC-MS/MS). (A-H) Plotted are the peak
intensities for detected amino acids. Data were presented as mean ± SEM and were
compared between cell groups by one-way ANOVA followed by Tukey’s post hoc test.
*p<0.05, **p<0.01, ***p<0.001.
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Figure 25. ME2 depletion alters acylcarnitine metabolism in HCC cells.
CRISPR/Cas9-mediated knockout of malic enzyme 2 (ME2) in PLC HCC cells was stably
produced by targeting two independent genomic regions; scramble guide RNA (sgScr)
was used as a control. Polar metabolites were isolated from the HCC cells and quantified
by liquid chromatography-tandem mass spectrometry (LC-MS/MS). (A-H) Plotted are the
peak intensities for detected acylcarnitines. Data were presented as mean ± SEM and
were compared between cell groups by one-way ANOVA followed by Tukey’s post hoc
test. **p<0.01, ***p<0.001.
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Figure 26. Liver-specific depletion of ME2 reduces tumor formation in a chemicallyinduced DEN model of HCC. Male, two-week-old Speer6-Cre-/-; ME2flox/flox (S-Mflox/flox),
Speer6-Cretg/+; ME2flox/WT (S+Mflox/WT), and Speer6-Cretg/+; ME2flox/flox (S+Mflox/flox) mice
(C57BL/6 background) were intraperitoneally injected with 75 mg/kg of diethylnitrosamine
(DEN) to chemically induce HCC. Mice were sacrificed eight months later and plotted are
their (A) average number of tumors and (B) liver to body weight ratio (Liver/body Weight)
(S-Mflox/flox, n= 10; S+Mflox/WT, n= 14; S+Mflox/flox, n= 18). Data were presented as mean ±
SEM and were compared between groups by one-way ANOVA followed by Tukey’s post
hoc test. *p<0.05, **p<0.01, ***p<0.001.
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Figure 27. Depletion of ME2 Liver-specific depletion of ME2 reduces tumor
formation in a chemically-induced DEN model of HCC. Female, two-week-old Speer6Cre-/-; ME2flox/flox (S-Mflox/flox), Speer6-Cretg/+; ME2flox/WT (S+Mflox/WT), and Speer6-Cretg/+;
ME2flox/flox (S+Mflox/flox) mice (C57BL/6 background) were intraperitoneally injected with 75
mg/kg of diethylnitrosamine (DEN) to chemically induce HCC. Mice were sacrificed eight
months later and their liver tissue assessed via immunohistochemistry. Representative
immunohistochemistry micrographs for (A) malic enzyme 2 (ME2), the proliferative marker
Ki67, and c-Myc were presented (n=3; scale bar= 100 µm). (B) Quantification of liver tissue
assessed via immunohistochemistry for Ki67 positive nuclei (n= 3). Data were presented
as mean ± SEM and were compared between groups by one-way ANOVA followed by
Tukey’s post hoc test. *p<0.05 and **p<0.01.
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Chapter 4: JNK Signaling Contributes to Skeletal Muscle
Wasting and Protein Turnover in Pancreatic Cancer
Cachexia
The following chapter contains work published in Cancer Letters, 2020 [283].

Introduction
Cancer remains a global burden despite advances in diagnostics and therapeutics,
and it is the second leading cause of death worldwide [284]. Cancer lethality can be
attributed to factors such as late diagnosis, drug resistance, metastasis, and recurrence.
However, cancer cachexia plays an under-appreciated role in cancer patient survival.
Cancer cachexia is a complex metabolic syndrome that manifests through systemic
inflammation, elevated protein catabolism, energy imbalance, and un-controllable loss of
lean body mass [102]. The syndrome not only impacts the quality of life of cancer patients
but also reduces the tolerance of treatments and survival [96]. Cachexia is highly prevalent
in cancer patients, as about half of all cancer patients are afflicted by the disease [285].
Cancer cachexia is most prevalent in gastrointestinal malignancies [94]. Compared to
other cancers, pancreatic cancer patients experience the syndrome at the highest rate of
80-85% [94, 96]. Approximately a third of pancreatic cancer patients ultimately succumb
to cachexia-associated complications [96]. When cachectic patients advance to a
refractory stage, they no longer respond to treatments aimed at improving appetite,
mitigating inflammation, or nutritional supplementation [102]. Therefore, there is a dire
need to identify molecular targets that are effective in combating cancer cachexia.
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Cancer cachexia is distinguished by several molecular characteristics that may be
therapeutically exploited. A prominent feature of muscle wasting is an elevated state of
proteolysis, which is due to increased amounts of autophagy and the induction of ubiquitin
ligases that cause muscle protein degradation via the ubiquitin proteasomal pathway
[286]. E3 ubiquitin ligases that are implicated in the pathogenesis of cachexia (Trim63)
[117, 287]. Previous studies have identified the role of p38 and extracellular signalregulated kinase (ERK) mitogen-activated protein kinases (MAPKs) in contributing to
elevated protein degradation in cachexia by inducing the expression of Trim63 and
Fbxo32 [288-290]. However, the potential roles of other MAPKs in cancer cachexia, such
as c-Jun N-terminal Kinase (JNK), are yet to be fully elucidated and may provide novel
therapeutic targets for better management of the disease.
JNK has known roles in normal muscle physiology. Activation of JNK signaling
negatively regulates skeletal muscle differentiation and is downregulated during
myogenesis [291]. Additionally, JNK regulates muscle remodeling by inhibiting myostatin
and SMAD2 [292]. A deficiency in JNK also has a metabolic impact, and it causes cultured
myotubes to increase fatty acid utilization, reduce glucose oxidation, and improves insulin
sensitivity [293]. The pharmacological inhibition of toll-like receptors with IMO-8503 has
been recently demonstrated to abrogate JNK-dependent muscle cell death in culture
conditions and in mice implanted with Lewis lung carcinoma cells [294]. However, the role
of JNK in other aspects of muscle homeostasis during cancer cachexia, such as protein
catabolism, remains unknown and the utility of direct targeting of JNK in ameliorating
cancer cachexia has not been established.
Here, we investigated the role of JNK in muscle catabolism in pancreatic cancerinduced cachexia. We performed reverse-phase protein array-based profiling of phosphoproteome to identify key signaling pathways in differentiated C2C12 myotube activated
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upon treatment with pancreatic cancer cell-conditioned media (CM). We identified an
upregulation in the phosphorylation of JNK and JNK-pathway proteins in myotubes
subjected to the CM. We confirmed that CM activates JNK in myotubes via
immunoblotting, and identified that pharmacological inhibition of JNK mitigates myotube
thinning and diminishes the expression of cachexia-related E3 ubiquitin ligases.
Intraperitoneal injection (IP) of the JNK inhibitor SP600125 in an orthotopic pancreatic
cancer mouse model significantly reduced cachexia as it abrogated body and muscle
weight loss, improved forelimb grip strength, and rescued myofiber atrophy. JNK inhibition
mitigated cancer cachexia, at least in part, by reducing the expression of proteolysisinducing E3 ubiquitin ligases.

Results
In vitro model of pancreatic cancer cell-induced muscle atrophy
activates JNK
To investigate the signaling pathways that contribute to muscle wasting in cancer
cachexia, we utilized an in vitro cancer cell-induced muscle fiber atrophy model in which
mouse C2C12-differentiated myotubes were treated with S2-013-conditioned media (CM)
to induce degeneration or atrophy. A reverse-phase protein array was utilized to examine
phospho-proteome differences between control and CM-treated myotubes, and an
elevation in JNK phosphorylation was observed in CM-treated samples (Figure 28A).
Increased phosphorylation was also observed in upstream activators and downstream
targets of JNK in CM-treated myotubes (Fig. 1B–C, respectively). Consistent with the
phosphorylation array data, JNK and c-Jun phosphorylation were elevated in CM-treated
myotubes when examined by immunoblot analysis (Figure 28D and 28E). CM-induced cJun phosphorylation in myotubes was abrogated by a range of dosages of the JNK activity
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inhibitor SP600125 (Figure 28E) [295]. Thus, cancer cell-secreted factors in the CM
induce JNK activation in myofibers in culture conditions.

JNK signaling contributes to myotube thinning
To investigate if JNK signaling has a functional role in myotube wasting, we
examined how inhibiting JNK activity altered myotube wasting parameters in our in vitro
model. JNK inhibition reduced CM-induced myotube thinning (Figure 29A and 29B). MyHC
is a prominent structural protein in myotubes and a proxy for wasting status [116].
Inhibiting JNK rescued MyHC protein levels of CM-treated myotubes in a dose-dependent
manner (Figure 29C). Protein degradation exhibited in cachectic muscle wasting is often
partially attributed to the upregulation of cachexia-related E3 ubiquitin ligases. CM
elevated the mRNA expression levels of genes coding for the E3 ubiquitin ligases, Trim63
and Fbxo32, and inhibition of JNK significantly mitigated their upregulation (Figure 29D
and 29E). Therefore, inhibiting JNK activation abrogates cancer cell-induced myofiber
atrophy in vitro, in part, by abrogating the expression of cachexia-associated ubiquitin
ligases.

Physiological impact of JNK inhibition in an orthotopic pancreatic
cancer model
Athymic nude mice were orthotopically implanted with S2-013 pancreatic cancer
cells (tumor-bearing; TB), and non-implanted mice served as healthy controls (HC). Mice
were given DMSO or SP600125 (10 mg/kg) via IP injections daily for five days a week
(Figure 30A). Fore-limb grip strength was also evaluated to assess muscle physiological
capacity, and JNK inhibition with SP600125 (TB + SP600125) partially abrogated the
reduction of grip strength observed in tumor-bearing mice (Figure 30B). The rotarod
performance in different groups showed trends similar to that of the grip strengths;
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however, the latency to fall in JNK inhibitor-treated tumor-bearing mice was not statistically
significant, in comparison to the solvent control-treated tumor-bearing mice (Fig. 30C).
Longitudinal measurements of tumor size showed no significant differences between
solvent control-treated and JNK inhibitor-treated tumor-bearing mice (Fig. 30D). Thus,
inhibition of JNK enhances the body weight of tumor-bearing mice in an orthotopic
pancreatic cancer mouse model and improves some physiological parameters of muscle
function.

JNK inhibition improves mouse body and skeletal muscle weights
measured upon necropsy
Healthy control mice and mice orthotopically implanted with pancreatic cancer cells
with or without JNK inhibitor treatment were sacrificed and evaluated. We observed that
JNK inhibition rescued the body weight loss in tumor-bearing mice when compared to
treatment with solvent control at day 21 (Fig. 31A). Measurement of carcass weight at day
27 also demonstrated that JNK inhibition abrogates weight loss in tumor-bearing mice
(Fig. 31B). JNK inhibitor treatment also rescued gastrocnemius muscle weight loss in
tumor-bearing mice (Fig. 31C). We observed no significant differences in tumor volume or
weight between JNK inhibitor and solvent control-treated mice (Fig. 31D–E). These data
suggest that JNK inhibition ameliorates the cachectic phenotype in tumor-bearing mice.

JNK inhibition ameliorates muscle wasting in an orthotopic pancreatic
tumor model
To examine if the elevated JNK activity was consistent in our orthotopic pancreatic
tumor model, we examined JNK activity via probing for c-Jun levels, a marker for JNK
activity, in the mouse muscle [296]. Total c-Jun levels were upregulated in the
gastrocnemius muscle from tumor-bearing mice, but the upregulation was abrogated in
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the JNK inhibitor-treated tumor-bearing group (Fig. 32A and 32B). To examine the
functional impact of this altered JNK activity, we measured the cross-sectional area of
gastrocnemius myofibers. The muscle fiber cross-sectional area was significantly reduced
in tumor-bearing mice as compared to healthy controls, and treatment of tumor-bearing
mice with SP600125 significantly rescued the cross-sectional area (Fig. 32A and 32C). To
evaluate the molecular contributions that could explain the differences in the muscle fiber
cross-sectional area, we examined the expression of cachexia-related E3 ubiquitin
ligases. The gastrocnemius muscle from tumor-bearing mice exhibited elevated mRNA
expression levels of the E3 ubiquitin ligases Trim63 and Fbxo32, and inhibition of JNK
abrogated their upregulation (Fig. 32D and 32E). Therefore, these data suggest that the
inhibition of JNK ameliorates muscle wasting in tumor-bearing mice by abolishing the
tumor-induced upregulation of cachexia-associated ubiquitin ligases.

Discussion & Future Directions
Cachexia frequently occurs in cancer and particularly in many gastrointestinal
malignancies, such as pancreatic cancer [297]. The occurrence of cancer cachexia not
only lessens the quality of life for cancer patients but also impairs tolerance of treatments
and overall survival [298]. The multifaceted syndrome is characterized by uncontrollable
weight loss, especially due to muscle wasting [94]. Muscle homeostasis is a balance of
anabolic and catabolic processes, and cancer cachexia tilts the equilibrium towards
catabolism. Muscle wasting is in part due to excessive protein turnover, which can be the
result of autophagy and proteasome-dependent protein degradation [286, 299]. Previous
studies have identified that the MAPKs p38 and ERK are known to induce the expression
of E3 ubiquitin ligases Fbxo32 and Trim63, but the role of the MAPK JNK in cachexia is
not fully elucidated [288, 289].
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This study demonstrates that JNK signaling directly contributes to skeletal muscle
protein turnover in pancreatic cancer cachexia and substantiates JNK as a possible
therapeutic target. Our studies suggest that JNK, as well as its upstream activators and
downstream targets, are activated in both in vitro and in vivo models of cancer cachexia.
JNK signaling is significant for the pathogenesis of cancer cachexia as inhibiting JNK
mitigated CM-induced thinning of differentiated C2C12 myotubes. Recently, it has been
identified that a TLR7/8/9 antagonist resulted in reduced levels of phosphorylated JNK
and lessened cancer cachexia in multiple models through inhibiting microRNA-induced
JNK-dependent cell death [294]. However, this study supports the notion that the improved
cancer cachexia phenotype seen from inhibiting JNK signaling is in part due to the
reduction of protein turnover. We assert this because the inhibition of JNK abrogated the
loss of the structural protein MyHC, and the treatment caused a drastic reduction in the
expression of cachexia-related E3 ubiquitin ligases Trim63 and Fbxo32. This in vitro data
supported the validity of JNK as a therapeutic target in cancer cachexia, and provided
rationale for further examination in a mouse model.
To further validate the significance of JNK signaling in muscle wasting and cancer
cachexia, we also utilized an orthotopic mouse model of pancreatic cancer. JNK inhibitor
treatment improved the body weight of tumor-bearing mice. Differences in body weight
can be in part attributed to the fact that JNK inhibitor treatment reduced the muscle wasting
as evident by improved muscle mass and myofiber cross-sectional area in tumor-bearing
mice. Importantly, the improvement in muscle mass had functional significance as it
improved the forelimb grip strength of tumor-bearing mice. Surprisingly, we did not
observe any reduction in tumor volume with JNK inhibitor treatment as previously
reported, but this may be due to differences in the mouse models and the higher dosages
previously used [300]. Overall, our data suggest that JNK signaling contributes to elevated
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protein turnover in skeletal muscle in cancer cachexia, but JNK may have other roles in
skeletal muscle or other organs.
While our evidence supports that JNK signaling contributes to skeletal muscle
expression of ubiquitin ligases in cancer cachexia, chemical inhibition of JNK in cachectic
tumor-bearing mice may have other systemic roles. Hypothalamic signaling has a
pleiotropic impact as it regulates appetite, energy expenditure, body weight, and glucose
homeostasis [301]. JNK inhibitor treatment in the hypothalamus has been shown to reduce
nutritional uptake in rats [302]. JNK is also activated in the brain of obese mice, and JNK1deficiency in the mouse central nervous system has also been shown to reduce body
mass and epididymal fat pad weight [303, 304]. Conversely, our in vivo model does not
experience over-nutrition seen in obesity. Instead, the cancer cachexia models are
nutritionally challenged because of cachexia-induced anorexia, and this difference may
contribute to weight gain in the JNK inhibitor-treated tumor-bearing mice.
The future directions of this work aim to expound upon the data observed in our
models of cachexia. We used an orthotopic implantation model of PDAC to induce cancer
cachexia, however expanding our findings into a spontaneous genetically engineered
mouse model of PDAC, such as the Kras+/G12D; Ptf1a+/ER-CRE; PTENf/f or Kras+/G12D;
p53+R172H/+; PDX1+/tg models, would be insightful as they contain a complete immune
system as well as better recapitulate tumor progression [305, 306]. Our data suggest that
JNK inhibition in our cachectic models impacts protein turnover, but we have yet to
investigate more broadly the global metabolic alterations that support the maintenance of
muscle in the context of cachexia. Therefore, we intend to evaluate both polar and lipid
metabolite pools via LC-MS/MS spectrometric analysis. While cachexia is not exclusive to
cancer, it is highly associated with the disease and even the chemotherapies used to treat
malignancies [307]. Therefore, we also aim to evaluate if JNK inhibition can mitigate the
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impact of chemotherapy-induced cachexia. Fat loss is characteristic in cancer cachexia,
so we additionally aspire to evaluate the impact of JNK inhibition on fat wasting in mouse
models of PDAC cancer cachexia [308].
Overall, our study identifies that pancreatic cancer induces JNK signaling in the
muscle that contributes to muscle wasting. We also demonstrate that pharmacological
inhibition of JNK mitigates muscle wasting, at least in part, by reducing protein turnover
and the expression of E3 ubiquitin ligases. We propose that the pharmacological inhibition
of JNK, alone or in combination with other MAPKs, warrants further investigation as a
targeted strategy component of a multimodal treatment for cancer cachexia.
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Figure 28. In vitro model of pancreatic cancer cachexia activates JNK. Differentiated
C2C12 myotubes were treated with control DMEM or S2-013-conditioned media (CM).
The phosphorylation status of (A) SAPK/JNK proteins, (B) upstream activators of
SAPK/JNK, and (C) downstream targets of SAPK/JNK was identified by a reverse-phase
protein array. (D) Immunoblot analysis for phosphorylated and total JNK in differentiated
C2C12 myotubes in response to treatment with control media or CM for 72 hours. (E)
Immunoblot analysis of phosphorylated and total c-Jun in differentiated C2C12 myotubes
in response to treatment with control media or CM with the indicated doses of JNK inhibitor
SP600125 for 72 hours.

100

101
Figure 29. JNK signaling contributes to myotube thinning. (A–B) Phase contrast
micrographs (A) of differentiated C2C12 myotubes treated with DMEM, S2-013conditioned media (CM), or CM and 500 nM SP600125 (CM + SP600125) for 72 hours
(scale bar= 250 μm) and bar chart (B) representing myotube width determined by ImageJ.
(C) Myotube wasting status assessed by immunoblotting for MyHC. The mRNA
expression of (D) Trim63 and (E) Fbxo32 in differentiated C2C12 myotubes treated with
DMEM, CM, or CM + SP600125 for 48 hours. Data are represented as mean ± SEM. Bar
charts were compared by one-way ANOVA followed by Tukey’s post hoc test. **p<0.01,
and ***p<0.001.
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Figure 30. Physiological impact of JNK inhibition on orthotopic pancreatic cancer
model. (A) Schematic illustration of experimental cohorts, experimental outline, and
course of treatment. Experimental groups of female athymic nude mice included tumorbearing (TB) mice orthotopically implanted with S2-013 pancreatic cancer cells, TB mice
treated with SP600125 (TB + SP600125), or unimplanted healthy control (HC) mice. Ten
days after implantation, the mice were treated once daily for five days a week with
SP600125 (10 mg/kg) or solvent control and sacrificed at 27 days post-implantation. (B)
Forelimb grip strength at indicated times as determined by a grip strength meter. (C)
Percent change in rotarod performance on day 21, compared to initial measurements on
day 11. (D) Longitudinal caliper measurements of tumor volume. Data in figures B, C, and
D are represented as mean ± SEM. The charts in (B and C) were compared by one-way
ANOVA followed by Tukey’s post hoc test. ***p<0.001 compared with the healthy control
mice group. #p<0.05 and ##p<0.01 compared with tumor-bearing mice group. Data in (D)
were compared by Student’s t-test at each time point.
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Figure 31. JNK inhibition improves mouse body weight and muscle weight. Mouse
necropsy measurements for female athymic nude mice included tumor-bearing (TB) mice
orthotopically implanted with S2-013 pancreatic cancer cells, TB mice treated with 10
mg/kg SP600125 (TB + SP600125), or unimplanted healthy control (HC) mice. (A) Body
weight (BW) at day 21 in comparison to the initial measurement on day 4. Bar charts
represent (B) carcass weight, (C) muscle weight, (D) tumor volume, and (E) tumor weight.
Data are represented as mean ± SEM. The bar charts in (A, B, C) were compared by oneway ANOVA followed by Tukey’s post hoc test. Data in (D and E) were compared by
Student’s t-test. *p<0.05 and **p<0.01.
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Figure 32. Inhibition of JNK ameliorates muscle wasting in a tumor-bearing mouse
model. (A) IHC staining for c-Jun and H&E in methacarn-fixed muscle sections from
female athymic nude mice; experimental groups included tumor-bearing (TB) mice
orthotopically implanted with S2-013 pancreatic cancer cells, TB mice treated with 10
mg/kg SP600125 (TB + SP600125), or unimplanted healthy control (HC) mice (scale bar=
100 μm). (B) Quantification of c-Jun staining and (C) muscle fiber cross-sectional area.
The mRNA expression of (D) Trim63 and (E) Fbxo32 from flash-frozen mouse
gastrocnemius muscle. Data are represented as mean ±SEM. Data were compared by
one-way ANOVA followed by Tukey’s post hoc test. *p<0.05 and **p<0.01.
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